CalciMedica Reports Strong Phase 2b Auxora Data in Acute Pancreatitis; Awaits FDA Feedback & Q1 Net Income
CALC sits 34% above its 52-week low of $0.461 on light trading volume (0.2× avg).
Summary
CalciMedica reported strong Phase 2b clinical trial results for its lead candidate Auxora in acute pancreatitis and achieved a Q1 net income driven by non-operating gains, with a cash runway into Q4 2026.
Key Events · Product Development and Regulatory · CALC
-
Strong Phase 2b Auxora Results
Detailed positive results from the Phase 2b CARPO trial for Auxora in acute pancreatitis (AP) were published, demonstrating clinically meaningful and statistically significant improvements, including a 100% reduction in new-onset severe respiratory failure.
-
Key FDA Milestones Ahead
The company expects FDA feedback in Q2 2026 on the pivotal program design for Auxora in AP and potential future development in acute kidney injury (AKI), following a positive safety review after pausing the AKI trial.
-
Q1 Net Income Driven by Non-Operating Gains
CalciMedica reported a net income of $5.0 million for Q1 2026, primarily due to a $10.8 million fair value adjustment of financial instruments, rather than operational profitability.
-
Limited Cash Runway
Cash and cash equivalents stood at $8.2 million as of March 31, 2026, with an expected cash runway into the fourth quarter of 2026, highlighting continued financing needs.
Analysis · CALC · Life Sciences
CalciMedica announced positive Phase 2b results for Auxora in acute pancreatitis, showing statistically significant reductions in severe respiratory failure and improved clinical outcomes. This strong data, coupled with expected FDA feedback in Q2 2026, is critical for the company's lead program. While Q1 showed a net income, it was primarily due to non-operating fair value adjustments, and the company's cash runway extends only into Q4 2026, indicating an ongoing need for financing.
At the time of this filing, CALC was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.